Duopharma Biotech Bhd.

Duopharma Biotech Bhd.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Duopharma Biotech Bhd. has 961.94M shares outstanding.

As of June 30, 2026, Duopharma Biotech Bhd. trades at a trailing price-to-earnings ratio of 11.20. The price-to-sales ratio is 1.23, and the price-to-book ratio stands at 1.46.

As of June 30, 2026, Duopharma Biotech Bhd. trades at an EV/EBITDA multiple of 8.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.95 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Duopharma Biotech Bhd. trades at an EV/FCF ratio of 10.89, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2026, Duopharma Biotech Bhd. maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.99, indicating elevated leverage, while an interest coverage ratio of 6.42 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Duopharma Biotech Bhd. posted a return on equity (ROE) of 13.43, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.26 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.11, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.67, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.94 indicates how many times Duopharma Biotech Bhd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended June 30, 2026. That works out to an effective tax rate of 23.90, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on October 22, 2026, Duopharma Biotech Bhd.'s stock has declined approximately 13.39% over the past 52 weeks. The 50-day moving average sits at 1.19, while the 200-day moving average is 1.27.

Over the twelve months ended June 30, 2026, Duopharma Biotech Bhd. posted a gross margin of 41.27, reflecting its pricing power and cost economics. The operating margin of 16.35 and net profit margin of 11.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 42.83 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.33, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.71, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Duopharma Biotech Bhd. shareholders.

Duopharma Biotech Bhd.'s most recent stock split took place on September 6, 2021 with a 3:4 split ratio.

As of June 30, 2026, Duopharma Biotech Bhd. has an Altman Z-Score of 2.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.